高視醫療(02407.HK)預期2024財年利潤減少約48.8%至53.6%
格隆匯3月7日丨高視醫療(02407.HK)發佈公告，相比截至2023年12月31日止財政年度錄得利潤淨額約人民幣172.9百萬元，預期集團於2024財年錄得利潤淨額約人民幣80.2百萬元至人民幣88.6百萬元，減少約48.8%至53.6%。
影響利潤淨額的主要因素情況如下：1. 儘管面對經濟環境及競爭壓力的影響，集團仍積極拓展其銷售領域，並依託成熟的銷售渠道、完善的售前支持及售後服務、優秀的市場推廣及產品組合策略，2024年下半年收入較2024年上半年收入實現顯著提升，2024財年收入相較2023財年保持基本穩定。然而受匯率波動、人工晶體國採政策執行等因素的影響，集團的綜合毛利率降低，使得毛利潤減少。
2. 應市場需求變化及競爭壓力，集團計劃調整電生理產品及視光產品戰略方向，受此調整，經謹慎考慮公司附屬公司Roland Consult Stasche &Finger GmbH和寧波高斯醫療科技有限公司近年來的經營狀況並結合管理層對未來市場的預期，集團預期會在2024財年對相關現金產生單元錄得的商譽計提減值撥備，估計金額約人民幣22.1百萬元至人民幣24.5百萬元。上述商譽減值撥備的短期影響並不會對集團未來的運營及現金流產生任何重大不利影響。
3. 集團緊隨國家戰略部署，持續加大研究及開發項目投入，加強自主創新能力建設，以確保中長期發展競爭力，於2024財年研發開支較2023財年顯著增加約人民幣21.6百萬元至人民幣29.4百萬元，且研發支出佔自有產品收入百分比持續增加。
4. 2024財年歐元持續位於高位，且美元走強，2024財年內人民幣兌外幣的匯率變動導致出現匯兌損失約人民幣5.4百萬元至人民幣6.0百萬元，而2023財年爲匯兌收益約人民幣15.6百萬元。
展望未來，公司對行業前景依然充滿信心，並將持續優化產品結構，加快產研工作步伐，深化銷售渠道拓展，不斷提升運營效率，努力實現業績的穩健增長與盈利水平的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
